Therefore, our data imply that targeting tumoral ASAP2 is potentially a more precise therapeutic strategy for inhibiting c-MET signaling in HCC with a minimal impact on c-MET activation in normal cells. Here, ASAP2 is linked to hepatocellular carcinoma.